参考；抗体薬物複合体の分析；TSKgel カラムを用いた非変性状態での分析と引用文献

薬物（ペイロード）の作用	主な薬物名	HPLC分離モードおよびTSKgelカラム使用例		主な文献
		SEC（凝集体分析）	HIC（DAR分析）	
チュブリン阻害	モノメチルアウリスタチンE (MMAE) モノメチルアウリスタチンF (MMAF) ドラスタチン	TSKgel UP-SW3000* TSKgel G3000SWXL	TSKgel HIC-ADC Butyl** TSKgel Butyl-NPR	1-8
	メイタンシノイド；DM1、DM4	TSKgel G3000SWXL	TSKgel Butyl-NPR	
DNA切断、損傷、副溝結合など	カリケアマイシン、オゾガマイシン	（推定；TSKgel G3000SWXL）	TSKgel Phenyl-5PW***	5, 9-12
	デュオカルマイシン	TSKgel G3000SWXL	TSKgel Butyl-NPR	
	ピロロベンゾジアゼピン (PBD) ピリジノベンゾジアゼピン (PDD)	TSKgel G3000SWXL	TSKgel Butyl-NPR	
トポイソメラーゼ I 阻害	カンプトテシン；MF-6、095 デルクステカン(Dxd)、イリノテカン ゴビテカン、エキサテカン；SN-38	TSKgel G3000SWXL	TSKgel Butyl-NPR	13-15
その他	STING作動薬；dSA3	TSKgel G3000SWXL	TSKgel Butyl-NPR	16-20
	BETたんぱく質阻害剤；EBET-2113			
	PROTAC	TSKgel SuperSW mAb HR	TSKgel Butyl-NPR	

* 現行品のTSKgel UP-SW3000-LSを推奨、 ** TSKgel HIC-ADC Phenylも応用可能、***TSKgel Phenyl-5PWはADC調整時の未反応抗体の定量

STING; Stimulator of interferon genes, BET; Bromodomain and extra-terminal protein degrader, PROTAC; Proteolysis targeting chimeras

文献

1. A. Goyon et al., Streamlined characterization of an antibody−drug conjugate by two-dimensional and four-dimensional liquid chromatography/Mass Spectrometry, Anal. Chem., 2019, 91, 14896−14903, http://dx.doi.org/10.1021/acs.analchem.9b02454
2. G. D. Healey et al., A RAGE-targeted antibody-drug conjugates: Surface plasmon resonance as a platform for accelerating effective ADC design and development Antibodies, 2019, 8, 7, https://doi.org/10.3390/antib8010007
3. Y. Wang et al., Antibody-drug conjugate using ionized Cys-linker MMAE as the potent payload shows optimal therapeutic safety, Cancers, 2020, 12, 744, https://doi.org/10.3390/cancers12030744
4. P. Probst et al., Broadening the therapeutic window of ADCs using site-specific bioconjugation showcased by an MMAE-containing peptide linker in a CD79b-targeting ADC, Mol. Cancer Ther., 2025, 24(6), https://doi.org/10.1158/1535-7163.MCT-24-0983
5. Phenyl-5PW, R. Hendricks et al., Simplified strategy for developing purification processes for antibody-drug conjugates using cation-exchange chromatography in flow-through mode, J. Chromatogr. A, 2022, 1666, 462865, https://doi.org/10.1016/j.chroma.2022.462865
6. H. E. Mohamed et al., Stability assessment of Polatuzumab vedotin and Brentuximab vedotin using different analytical techniques, J. Pharm. and Biomed. Anal., 2023, 228, 115249, https://doi.org/10.1016/j.jpba.2023.115249
7. X. Hu et al., Efficient and selective bioconjugation using surfactants, Bioconjugate Chem., 2018, 29, 3667−3676, http://dx.doi.org/10.1021/acs.bioconjchem.8b00594
8. T. Kempen et al., Online native hydrophobic interaction chromatography-mass spectrometry of antibody-drug conjugates, MABS, 2025, 17, No.1, 2446304, https://doi.org/10.1080/19420862.2024.2446304
9. R. G. E. Coumans, et al., A platform for the generation of site-specific antibody−drug conjugates that allows for selective reduction of engineered cysteines, Bioconjugate Chem., 2020, 31, 2136−2146, https://dx.doi.org/10.1021/acs.bioconjchem.0c00337
10. R. M. Hoffmann et al., A novel antibody-drug conjugate (ADC) delivering a DNA mono-alkylating payload to chondroitin sulfate proteoglycan (CSPG4)-expressing melanoma, Cancers, 2020, 12, 1029, https://doi.org/10.3390/cancers12041029
11. J. C. Cordova et al., Development of a single-step antibody–drug conjugate, J. Clin. Med., 2021, 10, 552. https://doi.org/10.3390/jcm10030552
12. R. Hendricks et al., Simplified strategy for developing purification processes for antibody-drug conjugates using cation-exchange chromatography in flow-through mode, J. Chromatogr. A, 2022, 1666, 462865, https://doi.org/10.1016/j.chroma.2022.462865
13. C. Kong et al., MTX-13, a novel PTK7-directed antibody–drug conjugate with widened therapeutic index shows sustained tumor regressions for a broader spectrum of PTK7-positive tumors, Mol Cancer Ther., 2023, 22:1128–43, https://doi.org/10.1158/1535-7163.mct-23-0164
14. T. Xiong et al., Design, synthesis, and evaluation of camptothecin-based antibody–drug conjugates with high hydrophilicity and structural stability, Molecules, 2025, 30, 1398, https://doi.org/10.3390/molecules30071398
15. R. Wang et al., Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor, Cell Reports Medicine, 2025, July 15, 6, 102213, https://doi.org/10.1016/j.xcrm.2025.102213
16. A. D. Hobson et al., Discovery of ABBV-154, an anti-TNF glucocorticoid receptor modulator immunology antibody-drug conjugate (iADC), J. Med. Chem., 2023, 66, 12544−12558, https://doi.org/10.1021/acs.jmedchem.3c01174
17. N. M. Cetinbas et al., Tumor cell-directed STING agonist antibody drug conjugates induce type III interferons and anti-tumor innate immune responses, Nature Communications, 2024, 15, 5842, https://doi.org/10.1038/s41467-024-49932-4
18. A. Cheung et al., Anti-EGFR antibody–drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth, Clin Cancer Res., 2024, 30, 3298–315, https://doi.org/10.1158/1078-0432.ccr-23-3110
19. S. Song et al., In silico-driven THIOMAB approach for stable PROTAC conjugates by docking payloads in antibody cavities, Bioconjugate Chem. 2025, 36, 960−970, https://doi.org/10.1021/acs.bioconjchem.4c00588
20. R. A. Bukhalid et al., XMT-2056, a HER2-directed STING agonist antibody–drug conjugate, induces innate antitumor immune responses by acting on cancer cells and tumor-resident immune cells, Clin Cancer Res., 2025, 31, 1766–82, https://doi.org/10.1158/1078-0432.ccr-24-2449